Sensorion

140 articles about Sensorion

• Sensorion Appoints Ex-Novartis Cell Therapy & Viral Vectors Head Otmane Boussif as Chief Technical Officer

  7/20/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the appointment of Otmane Boussif, a senior leader with extensive experience in managing global Chemistry, Manufacturing and Controls organizations, as Chief Technical Officer, effective August 1, 2021.

• Sensorion Appoints Gene Therapy and Rare Disease Expert Nora Yang as Chief Scientific Officer

  6/10/2021

  Sensorion announces the appointment of Nora Yang, Ph.D., a leader in gene therapy and rare diseases with extensive leadership experience in industry, academia, and government, as Chief Scientific Officer.

• Sensorion to Attend Two Conferences in June 2021

  5/27/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the participation of members of the company’s senior management team in two investor conferences being held virtually during June 2021.

• Sensorion Publishes Results of Combined General Meeting Resolutions

  5/18/2021

  Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the results of resolutions presented at its Combined General Meeting (CGM) on May 18, 2021and made them available on the dedicated section of its website.

• Sensorion to Attend Three Conferences in May 2021 Including ASGCT to Present a Poster and Co-Chair a Scientific Session

  5/4/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the participation of members of the company’s senior management team in three R&D and investor conferences being held virtually during May 2021.

• Sensorion Hosting Key Opinion Leader Webinar with Dr. Thomas Lenarz on the GJB2 Gene Related Hearing Loss on May 10, 2021

  4/30/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced that it will host a key opinion leader webinar on GJB2-Related Genetic Hearing Loss on Monday, May 10, 2021 at 10am Eastern Time.

• Sensorion Announces That a General Meeting of Shareholders Will Be Held Behind Closed Doors on May 18, 2021 Alongside the Publication of Its 2020 Annual Financial Report

  4/9/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the company's Board of Directors has approved the procedure for holding a Combined General Meeting behind closed doors on Tuesday, May 18, 2021.

• Sensorion Senior Management to Attend Four Conferences in April 2021

  3/31/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the participation of members of the company’s senior management team in four investor and R&D conferences being held virtually during April 2021.

• Sensorion Publishes Results of Extraordinary General Meeting Resolutions

  3/25/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the results of resolutions presented at its Extraordinary General Meeting on March 24, 2021 and made them available on the dedicated section of its website.

• Sensorion Reports Full-Year 2020 Financial Results and Provides Business Highlights

  3/18/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces its full-year 2020 financial results and provides an update on its business activities and outlook for 2021.

• Sensorion to Present at Two Conferences on March 16th 2021

  3/12/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the participation of management in two separate virtual conferences on March 16, 2021.

• Sensorion Presents New Preclinical Data on SENS-401 at ARO 2021

  2/19/2021

  SENS-401 yields significant treatment benefits in rats with severe hearing loss when initiated with a delay up to 7 days after the initial acoustic trauma

• Sensorion Announces That an Extraordinary General Meeting Will Be Held Behind Closed Doors on March 24, 2021

  2/17/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the company's Board of Directors has approved the procedure for holding an Extraordinary General Meeting behind closed doors on Wednesday, March 24, 2021.

• Sensorion : A Chardan Top Pick for 2021

  2/17/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the US healthcare investment bank Chardan decision to make Sensorion one of its top picks for 2021, calling the company “2021’s hidden gem in gene therapy”.

• Sensorion Announces Third Gene Therapy Collaboration With Institut Pasteur Targeting Important Pediatric and Adult Deafness Segments

  2/15/2021

  Key new findings by the Institut Pasteur concerning the gene target GJB2, enables Sensorion to potentially address important hearing loss segments in adults and children

• Sensorion Announces Preclinical Data Demonstrating SENS-401’s Potential to Preserve Residual Hearing After Cochlear Implantation

  1/19/2021

  Sensorion announces preclinical data showing that the combination of its SENS-401 molecule with cochlear implants reduced loss of residual hearing at a frequency located beyond the electrode array.

• Sensorion Announces Initiation of Coverage by Investment Banks Jefferies and Kempen With a “Buy” Recommendation

  1/7/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the investment banks Jefferies and Kempen have initiated analyst coverage of Sensorion.

• Sensorion Provides an Update on Plans and Progress in the Development of SENS-401 for the Prevention of Hearing Loss

  1/5/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces it plans to initiate a proof-of-concept clinical trial of SENS-401 to treat CIO in H2 2021.

• Sonova Invests €5 Million in Sensorion as the Companies Plan a Collaboration in Hearing Loss

  12/15/2020

  Sensorion announces that Sonova Holding AG, a leading provider of hearing solutions, will acquire a 3.7% ownership stake in Sensorion by way of subscription to a reserved share capital increase for total gross proceeds of €5 million.

• Sensorion Hosting Key Opinion Leader Call with Dr. John Greinwald on Genetic Hearing Loss in Children on December 2, 2020

  11/20/2020

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced that it will host a key opinion leader call on genetic hearing loss in children on Wednesday, December 2, 2020 at 8:00am Eastern Time.